Skip to main content
. Author manuscript; available in PMC: 2021 Aug 16.
Published in final edited form as: Clin Cancer Res. 2020 May 6;26(14):3662–3670. doi: 10.1158/1078-0432.CCR-20-0073

Figure 3. Concordant patient specific genomic alterations and peritonoid drug responses.

Figure 3.

Peritonoid dose response AUC data displayed as a violin plot for inhibitors of: (A) PARP; (B) PI3K; (C-D) EGFR. (A-C) Blue data points indicate the peritonoid with dose response curves displayed on right: (A) Patient 5 PTEN Y174H,K263; (B) Patient 1 PIK3CA N1044K; (C) Patient 3 EGFRAMP, ERBB2AMP, ERBB4AMP. Blue line on dose response curves is patient specific response, grey line indicates average response for previously screened cancer organoid and cell lines. AUC, area under the curve, AMP, copy number gain.